<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387699</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000508653</org_study_id>
    <secondary_id>ECOG-E1506</secondary_id>
    <nct_id>NCT00387699</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Bevacizumab in Combination With Cisplatin/Etoposide and Twice Daily Radiation for Patients With Limited-Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some find tumor cells and help kill them or carry tumor-killing substances to them.&#xD;
      Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also&#xD;
      stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy&#xD;
      uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with cisplatin,&#xD;
      etoposide, and radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bevacizumab together with cisplatin,&#xD;
      etoposide, and radiation therapy works in treating patients with limited-stage small cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the 1-year progression-free survival of patients with limited-stage small cell&#xD;
           lung cancer treated with bevacizumab, cisplatin, etoposide, and radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cisplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day&#xD;
      1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses&#xD;
      in the absence of disease progression or unacceptable toxicity. During course 1, patients&#xD;
      also undergo thoracic radiotherapy twice daily on days 1-5, 8-12, and 15-19.&#xD;
&#xD;
      Patients achieving a complete or partial response or stable disease after the first 4 courses&#xD;
      of chemotherapy continue to receive bevacizumab IV over 30-90 minutes on day 1. Treatment&#xD;
      with bevacizumab repeats every 21 days for up to 1 year in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Within 4-6 weeks after blood counts recover from the first 4 courses of chemotherapy,&#xD;
      patients achieving a complete or partial response also undergo prophylactic cranial&#xD;
      irradiation (PCI) in 10 fractions over 3 weeks.*&#xD;
&#xD;
      NOTE: *Bevacizumab should not be given for 3 weeks prior to or during PCI, but resumed 1 week&#xD;
      after completion of PCI.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 79 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer (SCLC)&#xD;
&#xD;
               -  Limited-stage disease, defined as SCLC confined to ≥ 1 of the following:&#xD;
&#xD;
                    -  One hemithorax&#xD;
&#xD;
                    -  Ipsilateral supraclavicular fossa&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No malignant pleural effusion, contralateral hilar disease, or contralateral&#xD;
             supraclavicular disease&#xD;
&#xD;
               -  Minimal pleural effusion visible on CT scan of the chest, but not evident on&#xD;
                  chest x-ray, allowed&#xD;
&#xD;
          -  No completely surgically resected disease&#xD;
&#xD;
          -  No CNS disease, including primary brain tumor or brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Urine protein:creatinine ratio ≤ 0.5 OR 24-hour urine protein &lt; 1,000 mg&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  INR ≤ 1.5 (unless on full-dose anticoagulants)&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No serious or nonhealing wound&#xD;
&#xD;
          -  No ulcer or bone fracture&#xD;
&#xD;
          -  No evidence of bleeding diatheses or coagulopathy&#xD;
&#xD;
          -  No hemoptysis&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products and/or other&#xD;
             recombinant human antibodies&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Cerebrovascular accident within the past 6 months&#xD;
&#xD;
               -  Symptomatic heart disease within the past 6 months&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Unstable angina within the past 6 months&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 4 weeks&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery or open biopsy&#xD;
&#xD;
          -  At least 1 week since prior core biopsy&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for small cell lung cancer&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No concurrent palliative local radiotherapy&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
          -  Concurrent full-dose anticoagulants (e.g., warfarin) allowed provided all of the&#xD;
             following criteria are met:&#xD;
&#xD;
               -  INR ≤ 3&#xD;
&#xD;
               -  In-range INR (2-3) on a stable dose of oral anticoagulant or on a stable dose of&#xD;
                  low molecular weight heparin&#xD;
&#xD;
               -  No active bleeding or pathological condition that carries a high risk of bleeding&#xD;
                  (e.g., tumor involving major vessels or known varices)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshin Dowlati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James A. Bonner, MD</last_name>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>limited stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

